Oncology/Anticancer API Products Manufacturer and Supplier
Dr. Reddy's is a global leader in developing APIs in the Oncology/Anti-cancer therapy area, with deep technical and scientific knowledge established over decades. With a strong presence across six continents and 39 countries, we are a partner of choice for supplying APIs to leading oncology formulators globally.
As one of the largest generic pharmaceutical manufacturers in the world, we have established a niche in generic oncology APIs and partner of choice for supplying APIs to leading oncology formulators globally.
Our various classes of API under anti-cancer portfolio are as follows:
Kinase Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
BCL-2 Inhibitor
*Countries referred in the above graphic denotes DMF filing geographies
Androgen Receptor (AR) Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Folate Analog Metabolic Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Nucleoside Metabolic Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Microtubule Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Proteasome Inhibitors
*Countries referred in the above graphic denotes DMF filing geographies
Thalidomide Analogue
*Countries referred in the above graphic denotes DMF filing geographies
CYP17 Inhibitor
*Countries referred in the above graphic denotes DMF filing geographies
Bifunctional Mechlorethamine
*Countries referred in the above graphic denotes DMF filing geographies
Nucleoside Metabolic Inhibitor
*Countries referred in the above graphic denotes DMF filing geographies
Alkylating Agent
*Countries referred in the above graphic denotes DMF filing geographies
Poly (ADP-ribose) Polymerase
*Countries referred in the above graphic denotes DMF filing geographies
CXCR4 Chemokine Receptor
*Countries referred in the above graphic denotes DMF filing geographies
GnRH Receptor Antagonist
*Countries referred in the above graphic denotes DMF filing geographies
Chemical Permeation Enhancer
*Countries referred in the above graphic denotes DMF filing geographies
Dr. Reddys Portfolio of Anti-cancer APIs
We manufacture our Anti-cancer APIs at cGMP API manufacturing facilities which are successfully inspected by international regulatory authorities such as the USFDA, EMEA, ANVISA, PMDA, and Health Canada.
Our team of process experts draws on their integrated understanding of IP, process development (API and formulation), and API manufacturing to ensure that by design, the process is lean, free from potential genotoxic impurities, and scalable to manufacture for early market entries. This is of particular importance to select the optimal synthesis route in the context of the IP situation. Other aspects are the solid-state forms and particle characteristics that are critical in formulation development.
We have incorporated sensitive and rigorous analytical methods to control the impurities at a specified level and extensively studied the flow properties, crystal size/shape, and morphology in accordance with future requirements. In addition, our APIs have been designed to address customized PSD requirements through size reduction and crystallization techniques, resulting in a high probability of successful formulation development.
